よむ、つかう、まなぶ。
資料４－２ 日本版抗コリン薬リスクスケール (42 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_40741.html |
| 出典情報 | 高齢者医薬品適正使用検討会（第18回 6／21）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
71.
Rafaelsen O, Clemmesen L, Lund H, Mikkelsen P, Bolwig T. Comparison of peripheral anticholinergic
effects of antidepressants: dry mouth. Acta Psychiatrica Scandinavica. 1981;63:364-9.
72.
Curran HV, Sakulsriprong M, Lader M. Antidepressants and human memory: an investigation of four
drugs with different sedative and anticholinergic profiles. Psychopharmacology. 1988;95:520-7.
73.
Dash V, Bawa M, Mahajan J, Kanojia RP, Samujh R, Rao K. Role of gabapentin and anticholinergics in
management of neurogenic bladder after repair of spina bifida–a randomized controlled study. Journal of
pediatric surgery. 2016;51(12):2025-9.
74.
Kay G, Crook T, Rekeda L, Lima R, Ebinger U, Arguinzoniz M, et al. Differential effects of the
antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. European urology.
2006;50(2):317-26.
75.
De La Cruz JF, Kisby C, Wu JM, Geller EJ. Impact of anticholinergic load on bladder function.
International Urogynecology Journal. 2015;26:545-9.
76.
Huang W-C, Yang AS-H, Hsiang-Te Tsai D, Shao S-C, Lin S-J, Lai EC-C. Association between recently
raised anticholinergic burden and risk of acute cardiovascular events: nationwide case-case-time-control
study. bmj. 2023;382.
77.
Myint PK, Fox C, Kwok CS, Luben RN, Wareham NJ, Khaw K-T. Total anticholinergic burden and risk
of mortality and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of
EPIC-Norfolk prospective population study. Age and ageing. 2015;44(2):219-25.
78.
Wang GS, Baker K, Ng P, Janis GC, Leonard J, Mistry RD, et al. A randomized trial comparing
physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome. Clinical Toxicology.
2021;59(8):698-704.
79.
Katoh T, Igawa Y, Yamaguchi O, Kato D, Hamada T, Kuroishi K. Cardiovascular safety of
antimuscarinic add‐on therapy in patients with overactive bladder who had a suboptimal response to
mirabegron monotherapy: a post hoc analysis from the Japanese MILAI II study. LUTS: Lower Urinary Tract
Symptoms. 2020;12(1):68-80.
80.
Choi J-Y, Kim H, Jung Y-i, Chun S, Yoo S, Lim J-Y, et al. Factors associated with anticholinergic burden
among older patients in long-term care hospitals in Korea. The Korean Journal of Internal Medicine.
2022;37(2):468.
81.
Wilson NM, Hilmer SN, March LM, Chen JS, Gnjidic D, Mason RS, et al. Associations between drug
burden index and mortality in older people in residential aged care facilities. Drugs & aging. 2012;29:157-65.
82.
Agar M, To T, Plummer J, Abernethy A, Currow DC. Anti-cholinergic load, health care utilization, and
survival in people with advanced cancer: a pilot study. Journal of Palliative Medicine. 2010;13(6):745-52.
83.
D’Alia S, Guarasci F, Bartucci L, Caloiero R, Guerrieri ML, Soraci L, et al. Hand grip strength may
affect the association between anticholinergic burden and mortality among older patients discharged from
hospital. Drugs & Aging. 2020;37:447-55.
84.
Campbell NL, Holden RJ, Tang Q, Boustani MA, Teal E, Hillstrom J, et al. Multicomponent behavioral
intervention to reduce exposure to anticholinergics in primary care older adults. J Am Geriatr Soc.
2021;69(6):1490-9.
85.
Liu AK, Possin KL, Cook KM, Lynch S, Dulaney S, Merrilees JJ, et al. Effect of collaborative dementia
care on potentially inappropriate medication use: Outcomes from the Care Ecosystem randomized clinical
trial. Alzheimer's & Dementia. 2023;19(5):1865-75.
42
Rafaelsen O, Clemmesen L, Lund H, Mikkelsen P, Bolwig T. Comparison of peripheral anticholinergic
effects of antidepressants: dry mouth. Acta Psychiatrica Scandinavica. 1981;63:364-9.
72.
Curran HV, Sakulsriprong M, Lader M. Antidepressants and human memory: an investigation of four
drugs with different sedative and anticholinergic profiles. Psychopharmacology. 1988;95:520-7.
73.
Dash V, Bawa M, Mahajan J, Kanojia RP, Samujh R, Rao K. Role of gabapentin and anticholinergics in
management of neurogenic bladder after repair of spina bifida–a randomized controlled study. Journal of
pediatric surgery. 2016;51(12):2025-9.
74.
Kay G, Crook T, Rekeda L, Lima R, Ebinger U, Arguinzoniz M, et al. Differential effects of the
antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. European urology.
2006;50(2):317-26.
75.
De La Cruz JF, Kisby C, Wu JM, Geller EJ. Impact of anticholinergic load on bladder function.
International Urogynecology Journal. 2015;26:545-9.
76.
Huang W-C, Yang AS-H, Hsiang-Te Tsai D, Shao S-C, Lin S-J, Lai EC-C. Association between recently
raised anticholinergic burden and risk of acute cardiovascular events: nationwide case-case-time-control
study. bmj. 2023;382.
77.
Myint PK, Fox C, Kwok CS, Luben RN, Wareham NJ, Khaw K-T. Total anticholinergic burden and risk
of mortality and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of
EPIC-Norfolk prospective population study. Age and ageing. 2015;44(2):219-25.
78.
Wang GS, Baker K, Ng P, Janis GC, Leonard J, Mistry RD, et al. A randomized trial comparing
physostigmine vs lorazepam for treatment of antimuscarinic (anticholinergic) toxidrome. Clinical Toxicology.
2021;59(8):698-704.
79.
Katoh T, Igawa Y, Yamaguchi O, Kato D, Hamada T, Kuroishi K. Cardiovascular safety of
antimuscarinic add‐on therapy in patients with overactive bladder who had a suboptimal response to
mirabegron monotherapy: a post hoc analysis from the Japanese MILAI II study. LUTS: Lower Urinary Tract
Symptoms. 2020;12(1):68-80.
80.
Choi J-Y, Kim H, Jung Y-i, Chun S, Yoo S, Lim J-Y, et al. Factors associated with anticholinergic burden
among older patients in long-term care hospitals in Korea. The Korean Journal of Internal Medicine.
2022;37(2):468.
81.
Wilson NM, Hilmer SN, March LM, Chen JS, Gnjidic D, Mason RS, et al. Associations between drug
burden index and mortality in older people in residential aged care facilities. Drugs & aging. 2012;29:157-65.
82.
Agar M, To T, Plummer J, Abernethy A, Currow DC. Anti-cholinergic load, health care utilization, and
survival in people with advanced cancer: a pilot study. Journal of Palliative Medicine. 2010;13(6):745-52.
83.
D’Alia S, Guarasci F, Bartucci L, Caloiero R, Guerrieri ML, Soraci L, et al. Hand grip strength may
affect the association between anticholinergic burden and mortality among older patients discharged from
hospital. Drugs & Aging. 2020;37:447-55.
84.
Campbell NL, Holden RJ, Tang Q, Boustani MA, Teal E, Hillstrom J, et al. Multicomponent behavioral
intervention to reduce exposure to anticholinergics in primary care older adults. J Am Geriatr Soc.
2021;69(6):1490-9.
85.
Liu AK, Possin KL, Cook KM, Lynch S, Dulaney S, Merrilees JJ, et al. Effect of collaborative dementia
care on potentially inappropriate medication use: Outcomes from the Care Ecosystem randomized clinical
trial. Alzheimer's & Dementia. 2023;19(5):1865-75.
42